$31.26

-0.02 (-0.06%)

Weekly Expected Move ±6.4%

$27 $29 $31 $33 $35

NASDAQ · Healthcare · Biotechnology · Alpha Radar Buy · Power 68 · $3.8B mcap · 116M float · 1.73% daily turnover · Short 57% of daily vol

Edge Score

Quantitative competitive moat analysis scoring five pillars of durable advantage — cost leadership, brand intangibles, switching costs, network effects, and efficient scale — using industry percentile rankings on a 0–100 scale.

WEAK EDGE

54.0 / 100

NoneWeakNarrowWide

Primary source: Network Effects · ROIC: 80.6% · 5Y Avg: 187.7%

Cost Advantage

Intangibles

Switching Cost

Network Effect

Scale

The Edge Score quantifies a company's competitive moat using five pillars: Cost Advantage (20%, operating margin and SG&A efficiency vs industry peers), Intangible Assets (25%, gross margin premium, R&D intensity, brand pricing power), Switching Costs (25%, revenue stability, earnings consistency, customer retention proxied by operating leverage), Network Effects (15%, revenue growth with expanding margins, market share dominance), and Efficient Scale (15%, market concentration, ROIC sustainability). Each pillar is scored 0–100 using industry percentile rankings, then weighted into a composite. Wide ≥ 70, Narrow ≥ 55, Weak ≥ 40, None < 40. CPRX shows a Weak competitive edge (54.0/100) — limited structural advantages that may face competitive pressure. The primary source of advantage is Network Effects. ROIC of 80.6% confirms the company is generating returns well above its cost of capital — a hallmark of durable competitive advantages.

Analyst Insights

Wall Street analyst consensus based on price targets and buy/sell/hold recommendations from institutional research coverage over the trailing 12 months.

Analyst Price Targets

$32

Low

$32

Avg Target

$32

High

Based on 2 analyst ratings (12 mo)

Analyst Recommendations

Strong Buy: 0Buy: 13Hold: 3Sell: 0Strong Sell: 0

Rating Summary

ConsensusBuy

Avg Target$32.00

Analysts1

Price Target Change History

Date	Firm	Analyst	Old	New	Change	Upside @ Call	Stock@Call
2026-05-07	Stephens	—	Initiated	$32	—	+2.8%	$31.12
2025-11-07	Oppenheimer	Leland Gershell	Initiated	$33	—	+52.4%	$21.66
2025-03-03	Robert W. Baird	—	$28	$32	+4	+43.4%	$22.32
2025-02-04	Robert W. Baird	Joel Beatty	Initiated	$28	—	+21.3%	$23.09
2025-01-10	H.C. Wainwright	Andrew Fein	$24	$35	+11	+59.7%	$21.92
2022-12-21	Truist Financial	—	$17	$18	+1	-6.0%	$19.15
2022-12-21	H.C. Wainwright	—	$18	$24	+6	+29.0%	$18.60
2022-12-19	Piper Sandler	Joseph Catanzaro	Initiated	$20	—	+21.9%	$16.41
2022-08-24	Roth Capital	Scott Henry	Initiated	$16	—	+4.0%	$14.91
2022-08-11	Truist Financial	—	Initiated	$17	—	+26.3%	$13.46
2022-08-11	H.C. Wainwright	—	Initiated	$18	—	+37.1%	$13.13

Financial Rating

Composite financial health rating (A+ to F) based on discounted cash flow valuation, return on equity, return on assets, debt-to-equity leverage, and relative P/E and P/B multiples.

A-

May 22, 2026

DCF

ROE

ROA

D/E

P/E

P/B

The Financial Rating evaluates six fundamental factors — discounted cash flow (DCF) valuation, return on equity (ROE), return on assets (ROA), debt-to-equity leverage (D/E), and relative price-to-earnings (P/E) and price-to-book (P/B) multiples — each scored 1–5. CPRX receives an overall rating of A-. Strongest factors: ROE (5/5), ROA (5/5), D/E (4/5). Areas of concern: DCF (2/5), P/E (2/5), P/B (2/5).

Rating Change History

Date	From	To
2026-04-24	B+	A-
2026-04-22	A-	B+
2026-03-24	A	A-
2026-03-02	A-	A
2026-02-26	A	A-

InsiderStreet Scorecard

Proprietary multi-factor scorecard rating companies across seven fundamental dimensions — profitability, balance sheet strength, earnings quality, growth, value, momentum, and safety — each scored 0–100.

★ ★ ★ ★ ★ 75 Grade A+

Profitability

100

Balance Sheet

Earnings Quality

Growth

Value

Momentum

Safety

100

Cash Flow

The InsiderStreet Scorecard rates companies across eight dimensions: Profitability (margins, ROA, ROE), Balance Sheet (leverage, liquidity, coverage), Earnings Quality (accruals, cash conversion), Growth (revenue and earnings trajectory), Value (P/E, P/B, earnings yield, Graham criteria), Momentum (revenue and earnings acceleration), Safety (Altman Z-Score risk adjustment), and Cash Flow (operating cash flow quality, FCF conversion, cash coverage). The overall score blends 35% quality, 35% value, and 30% momentum, with a penalty for distress-zone Altman scores. CPRX scores highest in Safety (100/100) and lowest in Growth (59/100). An overall grade of A+ places CPRX among the highest-quality companies in its peer group.

Risk & Quality Signals

Academic financial models used by institutional investors to assess bankruptcy risk, earnings manipulation, financial strength, and credit quality.

Altman Z-Score

15.13

Safe Zone

Piotroski F-Score

5/9

✓ ✓ ✗ ✗ ✓ ✓ ✓ ✗ ✗

Beneish M-Score

-1.60

Possible Manipulator

Ohlson O-Score

-12.92

Bankruptcy prob: 0.0%

Low Risk

Credit Rating

AA+

Score: 94.2/100

Trend: Stable

Earnings Quality

75/100

OCF/NI: 0.94x

Accruals: 1.3%

The Altman Z-Score (1968) combines five ratios — working capital, retained earnings, EBIT, market value of equity, and sales, all relative to total assets or liabilities — into a single bankruptcy predictor. CPRX scores 15.13, placing it in the Safe Zone (safe > 2.99, distress < 1.81). Bankruptcy is statistically unlikely within the next two years. The Piotroski F-Score (2000) is a 9-point binary checklist — four profitability tests (positive ROA, positive cash flow, improving ROA, cash flow exceeding net income), three leverage tests (declining debt ratio, improving current ratio, no share dilution), and two efficiency tests (improving gross margin, improving asset turnover). Each pass scores 1 point. CPRX scores 5/9, indicating moderate financial health — some areas of strength offset by weaknesses in others. The Beneish M-Score (1999) is an 8-variable model that detects earnings manipulation by comparing year-over-year changes in receivables, gross margins, asset quality, sales growth, depreciation, SG&A, leverage, and accruals. Scores above −1.78 statistically resemble past manipulators. CPRX's score of -1.60 exceeds the −1.78 red flag threshold — this does not confirm manipulation but indicates the earnings profile resembles past manipulators statistically. The Ohlson O-Score (1980) is a 9-variable logistic regression that estimates bankruptcy probability using firm size, leverage, working capital, current ratio, profitability (ROA), cash flow coverage, negative equity flag, consecutive losses flag, and earnings trajectory. The raw score is converted to a probability via logistic transformation. CPRX's implied 0.0% bankruptcy probability is well within safe territory. Our Credit Rating model scores companies on five weighted components — solvency (30%), earning power (25%), leverage (20%), liquidity (15%), and cash flow quality (10%) — then blends the absolute score with sector and industry peer rankings. For companies with large buyback programs, equity is adjusted by adding back cumulative 5-year repurchases (capped at 80% of FCF generated) to avoid penalizing shareholder-friendly capital allocation. CPRX receives an estimated rating of AA+ (score: 94.2/100), with a stable trend. The Earnings Quality score measures how well reported earnings are backed by real cash. It evaluates the operating cash flow to net income ratio (OCF/NI ≥ 1.0 means every dollar of earnings is cash-backed) and the accruals ratio (the gap between earnings and cash flow relative to assets — lower is better). CPRX's score of 75/100 is high — cash flows strongly support reported earnings.

Valuation

Key valuation multiples comparing the stock's market price to its earnings, revenue, book value, and cash flows. Lower multiples may indicate relative undervaluation versus peers.

P/E

17.27x

PEG

2.05x

P/S

6.41x

P/B

3.77x

P/FCF

15.10x

P/OCF

15.09x

EV/EBITDA

7.77x

EV/Revenue

4.08x

EV/EBIT

8.84x

EV/FCF

11.70x

Earnings Yield

7.04%

FCF Yield

6.62%

Shareholder Yield

1.27%

Graham Number

$17.18

Equity-based multiples (P/E, P/B, P/FCF) compare the stock price to per-share fundamentals and are affected by capital structure. Enterprise value multiples (EV/EBITDA, EV/Revenue, EV/FCF) strip out debt and cash, making them more useful for cross-company comparisons regardless of how companies are financed. The Graham Number — √(22.5 × EPS × Book Value) — is Benjamin Graham's formula for the maximum price a defensive investor should pay. At 17.3x earnings, CPRX trades at a reasonable valuation. An earnings yield of 7.0% exceeds typical risk-free rates, suggesting equities are being compensated for risk. Graham's intrinsic value formula yields $17.18 per share, 82% below the current price.

DuPont Decomposition (5-Factor)

The 5-factor DuPont framework breaks Return on Equity into its component drivers — tax efficiency, interest burden, operating profitability, asset utilization, and financial leverage — to reveal what truly drives shareholder returns.

Tax Burden

0.747

NI / EBT

Interest Burden

1.076

EBT / EBIT

EBIT Margin

0.461

EBIT / Rev

Asset Turnover

0.610

Rev / Assets

Equity Multiplier

1.164

Assets / Equity

ROE

26.3%

The 5-factor DuPont identity decomposes ROE as: Tax Burden × Interest Burden × EBIT Margin × Asset Turnover × Equity Multiplier = ROE. This reveals whether returns are driven by operating performance, financial leverage, or tax efficiency — three very different sources of profitability. CPRX's ROE of 26.3% is driven by Asset Turnover (0.610), indicating efficient use of assets to generate revenue.

Graham-Dodd Adjusted Valuation

Our adaptation of Graham's growth formula (Fair P/E = 8.5 + 2g) from The Intelligent Investor. The classic version relies on analyst growth projections, which can be unreliable. This adjusted model substitutes the company's realized 3-year EPS CAGR — a backward-looking, verifiable measure of actual earnings power — grounding the valuation in demonstrated performance rather than forecasts.

Adj. Growth Rate

25.99%

Fair P/E

60.48x

Intrinsic Value

$105.47

Price/Value

0.23x

Margin of Safety

76.52%

Premium

-76.52%

Assessment

Undervalued

Graham's classic formula uses analyst-projected growth to estimate a fair P/E (8.5 + 2g). Our adjusted version replaces that projection with CPRX's realized 26.0% 3-year EPS CAGR — what the company actually delivered, not what analysts hope for. At an intrinsic value of $105.47, CPRX appears undervalued with a 77% margin of safety. The adjusted fair P/E of 60.5x compares to the current market P/E of 17.3x.

Profitability Trends

Historical profitability ratios tracking how efficiently the company converts revenue into returns for shareholders over time.

Leverage & Solvency Trends

Debt and liquidity metrics showing the company's financial leverage and ability to meet short-term and long-term obligations.

Efficiency & Working Capital Trends

Operating efficiency metrics measuring how quickly the company converts inventory to sales, collects receivables, and manages its cash conversion cycle.

Growth Trends (YoY %)

Year-over-year growth rates for key financial metrics, showing the trajectory of revenue, earnings, and cash flow generation.

Earnings Stability

R-squared of linear regression measuring how predictably revenue, earnings, and margins follow a trend over the trailing 5 years. 1.0 = perfectly predictable; lower values indicate erratic or cyclical behavior.

Monte Carlo Price Simulation

Geometric Brownian Motion with 1,000 antithetic paths over 1 year, seeded from 1800 days of historical volatility. Percentile bands show the range of statistically plausible outcomes — this is a statistical model, not a forecast.

Current Price

$31.26

Median 1Y

$33.67

5th Pctile

$13.51

95th Pctile

$85.28

Ann. Volatility

59.3%

Analyst Target

$32.00

25th–75th percentile 5th–95th percentile Median path Historical Analyst target

Executive Compensation

C-suite compensation breakdown including salary, stock awards, options, and incentive pay. The CEO-to-employee pay ratio and Gini coefficient measure pay distribution fairness.

C-Suite Compensation

Executive	Salary	Stock	Total
Richard J. Daly, President and CEO	$750,000	$—	$7,774,160
Michael W. Kalb, EVP and CFO	$525,000	$—	$6,180,936
Steven R. Miller, COO and CSO	$560,000	$—	$3,545,774
Jeffrey Del Carmen, CCO	$525,000	$—	$2,638,127
Preethi Sundaram, Strategy rategy Officer	$485,000	$—	$2,528,555

CEO Pay Ratio

7:1

CEO-to-Employee Pay Ratio

CEO Total Comp: $7,774,160

Avg Employee Cost (SGA/emp): $1,064,566

Employees: 182

C-Suite Pay Equality (Gini)

CEO Compensation Mix

Workforce & Productivity

Workforce efficiency metrics measuring revenue, profit, and R&D spend per employee — key indicators of operational leverage and human capital productivity.

Employees

182

+0.6% YoY

Revenue / Employee

$3,236,203

Rev: $588,989,000

Profit / Employee

$1,177,615

NI: $214,326,000

SGA / Employee

$1,064,566

Avg labor cost proxy

R&D / Employee

$69,830

Innovation spend

Scaling Efficiency

All Ratios & Metrics

Complete fundamental data with up to 20 periods of history, sparkline trends, and current values across 13 categories and 130+ financial metrics.

Profitability

Metric	Q2'21	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Current
ROE	58.0%	32.4%	21.0%	23.9%	29.0%	35.6%	32.8%	39.2%	45.6%	24.5%	20.7%	18.9%	19.8%	41.5%	29.4%	35.4%	37.4%	39.0%	25.5%	26.3%	26.32%
ROA	49.0%	27.3%	18.4%	21.0%	25.3%	31.1%	27.1%	32.4%	37.7%	20.2%	16.9%	15.4%	16.1%	33.8%	24.8%	29.9%	31.6%	32.9%	21.9%	22.6%	22.60%
ROIC	2.5%	1.4%	2.0%	2.3%	2.8%	3.4%	13.6%	16.2%	18.6%	9.8%	25.8%	23.3%	24.6%	51.8%	69.3%	82.8%	87.6%	92.4%	78.6%	80.6%	80.61%
ROCE	27.1%	28.5%	24.9%	28.4%	34.5%	39.8%	32.7%	38.5%	44.2%	24.6%	22.0%	19.9%	21.8%	44.1%	26.7%	31.7%	33.7%	36.5%	27.7%	28.7%	28.70%
Gross Margin	87.5%	85.2%	80.8%	86.3%	85.6%	83.1%	81.6%	88.3%	87.9%	86.2%	85.7%	87.3%	87.4%	85.0%	84.7%	87.3%	79.6%	82.9%	82.9%	83.8%	83.82%
Operating Margin	43.6%	38.9%	33.3%	40.3%	53.8%	43.9%	50.7%	41.7%	46.9%	-36.2%	37.7%	27.5%	44.2%	39.6%	44.3%	44.8%	45.2%	44.7%	40.5%	49.0%	49.02%
Net Margin	33.5%	28.7%	24.3%	30.7%	40.7%	39.7%	41.9%	34.6%	37.9%	-30.0%	31.5%	23.6%	33.2%	34.1%	39.4%	40.1%	35.6%	35.6%	34.5%	42.7%	42.66%
EBITDA Margin	43.6%	39.0%	33.3%	40.4%	53.9%	44.8%	55.4%	49.4%	55.5%	-27.9%	46.0%	37.1%	51.9%	39.6%	51.0%	51.5%	53.7%	54.2%	46.8%	55.6%	55.61%
FCF Margin	34.0%	39.9%	42.1%	42.2%	44.2%	49.6%	54.2%	-16.7%	-12.6%	-9.9%	-5.3%	39.1%	44.7%	48.2%	48.7%	50.0%	49.2%	40.6%	35.4%	34.9%	34.86%
OCF Margin	34.7%	40.7%	42.9%	42.3%	44.3%	49.6%	54.2%	46.6%	41.0%	36.7%	36.1%	39.7%	45.3%	48.8%	48.8%	50.1%	49.3%	40.6%	35.4%	34.9%	34.88%
ROE 3Y Avg	snapshot only																				22.37%
ROE 5Y Avg	snapshot only																				24.40%
ROA 3Y Avg	snapshot only																				19.01%
ROIC Economic	snapshot only																				21.14%
Cash ROA	snapshot only																				18.81%
Cash ROIC	snapshot only																				84.00%
CROIC	snapshot only																				83.96%
NOPAT Margin	snapshot only																				33.47%
Pretax Margin	snapshot only																				49.66%
R&D / Revenue	snapshot only																				1.92%
SGA / Revenue	snapshot only																				32.86%
SBC / Revenue	snapshot only																				3.17%

Valuation

Metric	Q2'21	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Current
P/E Ratio	8.30	13.74	18.68	20.06	14.05	21.47	25.42	19.01	13.22	20.08	26.78	30.21	28.33	17.46	16.08	15.60	13.26	11.51	13.86	14.20	17.267
P/S Ratio	4.88	4.28	5.24	5.88	4.49	7.49	9.86	7.37	5.04	3.58	4.80	4.78	4.44	5.41	5.36	5.76	4.96	4.33	5.04	5.26	6.409
P/B Ratio	3.65	3.37	3.57	4.37	3.70	6.95	7.03	6.29	5.09	4.15	4.93	5.07	4.98	6.43	3.62	4.23	3.80	3.44	3.11	3.29	3.774
P/FCF	14.37	10.72	12.43	13.92	10.16	15.11	18.20	-44.20	-40.03	-36.21	-90.42	12.23	9.94	11.24	11.02	11.51	10.07	10.67	14.24	15.10	15.097
P/OCF	14.06	10.53	12.22	13.90	10.14	15.10	18.20	15.80	12.30	9.73	13.32	12.03	9.81	11.10	10.99	11.49	10.06	10.67	14.23	15.09	15.091
EV/EBITDA	10.38	8.90	10.47	11.93	7.95	14.80	17.25	12.26	7.86	9.28	14.86	16.07	14.67	11.68	9.49	9.87	8.20	6.54	7.46	7.77	7.765
EV/Revenue	3.78	3.23	3.91	4.66	3.40	6.52	8.48	6.22	4.07	2.73	4.47	4.46	4.14	5.12	4.31	4.80	4.03	3.44	3.84	4.08	4.080
EV/EBIT	10.43	8.94	10.51	11.96	7.96	14.92	17.47	13.05	8.78	12.18	20.48	23.40	20.92	13.56	10.87	11.08	9.14	7.46	8.53	8.84	8.844
EV/FCF	11.11	8.09	9.28	11.04	7.68	13.14	15.66	-37.31	-32.31	-27.65	-84.08	11.39	9.25	10.64	8.87	9.58	8.20	8.48	10.85	11.70	11.703
Earnings Yield	12.0%	7.3%	5.4%	5.0%	7.1%	4.7%	3.9%	5.3%	7.6%	5.0%	3.7%	3.3%	3.5%	5.7%	6.2%	6.4%	7.5%	8.7%	7.2%	7.0%	7.04%
FCF Yield	7.0%	9.3%	8.0%	7.2%	9.8%	6.6%	5.5%	-2.3%	-2.5%	-2.8%	-1.1%	8.2%	10.1%	8.9%	9.1%	8.7%	9.9%	9.4%	7.0%	6.6%	6.62%
PEG Ratio	snapshot only																				2.047
Price/Tangible Book	snapshot only																				3.820
EV/OCF	snapshot only																				11.698
EV/Gross Profit	snapshot only																				4.956
Acquirers Multiple	snapshot only																				9.101
Shareholder Yield	snapshot only																				1.27%
Graham Number	snapshot only																				$17.18

Leverage & Solvency

Metric	Q2'21	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Current
Current Ratio	7.00	7.00	7.76	7.76	7.76	7.76	5.57	5.57	5.57	5.57	2.88	2.88	2.88	2.88	5.17	5.17	5.17	5.17	6.08	6.08	6.076
Quick Ratio	6.79	6.79	7.47	7.47	7.47	7.47	5.45	5.45	5.45	5.45	2.68	2.68	2.68	2.68	5.01	5.01	5.01	5.01	5.82	5.82	5.823
Debt/Equity	0.00	0.00	0.02	0.02	0.02	0.02	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.003
Net Debt/Equity	-0.83	-0.83	-0.90	-0.90	-0.90	-0.90	-0.98	-0.98	-0.98	-0.98	-0.35	-0.35	-0.35	-0.35	-0.71	-0.71	-0.71	-0.71	-0.74	-0.74	-0.740
Debt/Assets	0.00	0.00	0.02	0.02	0.02	0.02	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.003
Debt/EBITDA	0.00	0.00	0.08	0.07	0.06	0.05	0.04	0.03	0.02	0.04	0.03	0.03	0.03	0.02	0.01	0.01	0.01	0.01	0.01	0.01	0.009
Net Debt/EBITDA	-3.04	-2.89	-3.56	-3.11	-2.57	-2.22	-2.80	-2.26	-1.88	-2.87	-1.12	-1.18	-1.09	-0.66	-2.30	-1.98	-1.87	-1.69	-2.33	-2.25	-2.252
Interest Coverage	—	—	—	—	—	—	—	—	—	294.82	327.59	295.58	324.06	—	—	—	—	—	—	—	—
Equity Multiplier	1.13	1.13	1.15	1.15	1.15	1.15	1.25	1.25	1.25	1.25	1.21	1.21	1.21	1.21	1.17	1.17	1.17	1.17	1.16	1.16	1.160
Cash Ratio	snapshot only																				4.819
Cash to Debt	snapshot only																				254.457
FCF to Debt	snapshot only																				74.679
Defensive Interval	snapshot only																				1365.8 days

Efficiency & Turnover

Metric	Q2'21	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Current
Asset Turnover	0.83	0.88	0.65	0.71	0.79	0.89	0.70	0.84	0.99	1.14	0.94	0.97	1.03	1.09	0.74	0.81	0.85	0.88	0.60	0.61	0.610
Inventory Turnover	5.44	5.87	3.50	3.69	4.18	4.88	4.69	5.24	5.84	6.45	4.63	4.86	5.16	5.61	3.91	4.22	5.05	5.39	3.50	3.72	3.722
Receivables Turnover	15.36	16.16	22.34	24.39	27.05	30.42	25.11	30.07	35.52	40.85	12.45	12.86	13.59	14.40	8.27	8.99	9.39	9.72	6.14	6.22	6.220
Payables Turnover	4.29	4.64	6.23	6.58	7.46	8.70	10.20	11.40	12.71	14.05	5.54	5.81	6.17	6.71	4.39	4.73	5.66	6.04	7.14	7.59	7.593
DSO	24	23	16	15	13	12	15	12	10	9	29	28	27	25	44	41	39	38	59	59	58.7 days
DIO	67	62	104	99	87	75	78	70	62	57	79	75	71	65	93	86	72	68	104	98	98.1 days
DPO	85	79	59	56	49	42	36	32	29	26	66	63	59	54	83	77	65	60	51	48	48.1 days
Cash Conversion Cycle	6	6	62	58	52	45	57	50	44	40	42	41	38	36	54	50	47	45	113	109	108.7 days
Fixed Asset Turnover	snapshot only																				200.861
Operating Cycle	snapshot only																				156.8 days
Cash Velocity	snapshot only																				0.842
Capital Intensity	snapshot only																				1.854

Growth (YoY)

Metric	Q2'21	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Current
Revenue	6.0%	13.0%	18.3%	27.9%	34.3%	43.6%	52.1%	66.9%	77.7%	81.7%	85.9%	60.4%	43.4%	32.2%	23.5%	30.0%	28.5%	25.6%	19.8%	11.7%	11.65%
Net Income	78.7%	-41.8%	-47.3%	-37.6%	-27.0%	60.8%	1.1%	1.2%	1.1%	-7.3%	-14.0%	-34.5%	-41.0%	1.3%	1.3%	2.0%	2.1%	52.4%	30.8%	12.1%	12.15%
EPS	77.0%	-42.6%	-48.9%	-39.0%	-28.0%	54.9%	1.0%	1.1%	1.0%	-2.6%	-14.2%	-39.5%	-46.2%	95.6%	1.1%	1.9%	2.0%	50.3%	29.8%	12.2%	12.20%
FCF	-12.1%	20.6%	31.8%	59.5%	74.9%	78.3%	95.5%	-1.7%	-1.5%	-1.4%	-1.2%	4.8%	6.1%	7.4%	12.3%	66.3%	41.4%	5.7%	-12.8%	-22.2%	-22.21%
EBITDA	6.9%	18.0%	26.9%	48.1%	57.8%	74.3%	1.0%	1.2%	1.2%	21.4%	13.6%	-12.4%	-21.9%	97.0%	86.7%	1.3%	1.2%	50.7%	35.8%	20.8%	20.77%
Op. Income	7.3%	18.6%	26.8%	48.4%	58.1%	73.6%	94.4%	1.0%	90.2%	-9.4%	-14.8%	-34.8%	-37.9%	1.3%	1.2%	2.0%	1.8%	48.7%	32.1%	15.7%	15.68%
OCF Growth	snapshot only																				-22.29%
Asset Growth	snapshot only																				30.00%
Equity Growth	snapshot only																				31.15%
Debt Growth	snapshot only																				-12.58%
Shares Change	snapshot only																				-0.04%

Growth (CAGR)

Metric	Q2'21	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Current
Revenue 3Y	—	—	5.6%	1.3%	59.8%	38.2%	27.9%	29.2%	36.3%	43.4%	49.5%	50.7%	50.7%	51.1%	51.7%	51.5%	48.5%	44.5%	40.1%	32.5%	32.52%
Revenue 5Y	—	—	—	—	—	—	—	—	—	—	2.8%	99.7%	59.7%	44.7%	36.9%	35.1%	36.1%	37.4%	37.7%	37.8%	37.80%
EPS 3Y	—	—	—	—	—	89.2%	34.7%	29.3%	37.5%	-4.7%	-4.0%	-8.0%	-7.6%	43.4%	53.0%	55.5%	48.6%	42.0%	32.0%	26.0%	25.99%
EPS 5Y	—	—	—	—	—	—	—	—	—	—	—	—	—	66.8%	34.1%	31.0%	33.1%	20.6%	18.9%	20.8%	20.84%
Net Income 3Y	—	—	—	—	—	92.1%	37.6%	32.3%	40.4%	-4.6%	-1.6%	-3.4%	-3.0%	50.8%	60.7%	63.6%	56.4%	48.1%	37.1%	30.6%	30.58%
Net Income 5Y	—	—	—	—	—	—	—	—	—	—	—	—	—	72.1%	38.7%	35.7%	38.0%	24.9%	23.4%	25.1%	25.10%
EBITDA 3Y	—	—	—	—	—	1.1%	48.6%	43.7%	53.7%	35.7%	42.4%	41.1%	38.4%	60.9%	62.0%	62.9%	55.7%	53.3%	42.3%	34.1%	34.07%
EBITDA 5Y	—	—	—	—	—	—	—	—	—	—	—	—	—	86.4%	47.4%	42.7%	44.8%	49.3%	48.9%	50.5%	50.55%
Gross Profit 3Y	—	—	—	—	84.8%	44.1%	27.1%	28.9%	36.3%	43.6%	50.3%	51.5%	51.2%	51.6%	52.6%	52.2%	48.2%	44.2%	39.7%	31.1%	31.11%
Gross Profit 5Y	—	—	—	—	—	—	—	—	—	—	—	—	75.1%	49.1%	37.0%	35.2%	35.5%	36.6%	36.8%	36.8%	36.80%
Op. Income 3Y	—	—	—	—	—	1.1%	47.4%	40.3%	47.8%	23.1%	28.1%	24.7%	23.2%	53.3%	55.0%	56.9%	49.6%	45.6%	36.3%	30.6%	30.63%
Op. Income 5Y	—	—	—	—	—	—	—	—	—	—	—	—	—	80.9%	43.7%	39.7%	41.6%	44.8%	44.2%	46.0%	45.96%
FCF 3Y	—	—	—	—	—	89.7%	49.7%	—	—	—	—	58.1%	65.2%	60.8%	59.2%	60.3%	53.9%	35.1%	21.6%	—	—
FCF 5Y	—	—	—	—	—	—	—	—	—	—	—	—	—	73.9%	47.2%	40.0%	41.1%	39.6%	35.9%	38.6%	38.59%
OCF 3Y	—	—	—	—	—	89.4%	49.7%	33.9%	36.3%	42.5%	47.2%	57.8%	64.7%	60.5%	58.4%	60.3%	53.8%	35.1%	21.6%	20.3%	20.29%
OCF 5Y	—	—	—	—	—	—	—	—	—	—	—	—	—	74.2%	47.3%	40.0%	41.2%	39.6%	35.9%	38.0%	37.98%
Assets 3Y	31.1%	31.1%	57.9%	57.9%	57.9%	57.9%	49.5%	49.5%	49.5%	49.5%	34.7%	34.7%	34.7%	34.7%	53.0%	53.0%	53.0%	53.0%	43.4%	43.4%	43.36%
Assets 5Y	26.2%	26.2%	41.6%	41.6%	41.6%	41.6%	34.5%	34.5%	34.5%	34.5%	50.7%	50.7%	50.7%	50.7%	49.9%	49.9%	49.9%	49.9%	41.9%	41.9%	41.90%
Equity 3Y	28.0%	28.0%	59.7%	59.7%	59.7%	59.7%	50.8%	50.8%	50.8%	50.8%	31.8%	31.8%	31.8%	31.8%	52.1%	52.1%	52.1%	52.1%	47.0%	47.0%	47.00%
Book Value 3Y	25.9%	25.9%	56.6%	56.6%	58.1%	57.3%	47.6%	47.4%	47.7%	50.7%	28.6%	25.5%	25.5%	25.3%	44.8%	44.6%	44.4%	45.8%	41.5%	41.8%	41.83%
Dividend 3Y	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

Growth Quality

Metric	Q2'21	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Current
Revenue Stability	0.81	0.85	0.83	0.85	0.95	0.99	0.96	0.92	0.91	0.90	0.89	0.92	0.91	0.89	0.86	0.88	0.91	0.94	0.96	0.98	0.977
Earnings Stability	0.75	0.69	0.63	0.68	0.80	0.76	0.75	0.80	0.89	0.65	0.63	0.57	0.58	0.65	0.62	0.55	0.58	0.68	0.72	0.71	0.708
Margin Stability	0.76	0.92	0.00	0.00	0.80	0.93	0.99	1.00	0.99	0.99	0.00	0.05	0.83	0.94	0.99	0.99	0.99	0.98	0.98	0.98	0.980
Rev. Growth Consistency	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.000
Earn. Growth Consistency	1.00	0.00	0.00	0.00	0.00	0.50	0.50	0.50	0.50	0.00	0.00	0.00	0.00	0.50	0.50	0.50	0.50	1.00	1.00	1.00	1.000
FCF Positive Streak	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	1	1	1	1	1	1
Earnings Persistence	0.50	0.83	0.81	0.85	0.89	0.50	0.50	0.50	0.50	0.97	0.94	0.86	0.84	0.50	0.50	0.50	0.50	0.50	0.88	0.95	0.951
Earnings Smoothness	0.44	0.47	0.38	0.54	0.69	0.53	0.29	0.25	0.28	0.92	0.85	0.58	0.48	0.21	0.21	0.00	0.00	0.59	0.73	0.89	0.885
ROE Trend	0.32	-0.26	-0.21	-0.24	-0.19	-0.21	-0.04	0.01	0.03	-0.08	-0.05	-0.11	-0.15	0.10	-0.01	0.02	0.01	0.01	0.02	0.01	0.012
Gross Margin Trend	0.16	0.05	-0.01	-0.00	-0.01	-0.02	-0.01	-0.00	0.01	0.02	0.03	0.02	0.01	0.01	0.01	0.00	-0.02	-0.03	-0.03	-0.04	-0.041
FCF Margin Trend	0.24	0.12	0.06	0.04	0.07	0.11	0.14	-0.55	-0.52	-0.55	-0.53	0.26	0.29	0.28	0.24	0.39	0.33	0.21	0.14	-0.10	-0.097
Sustainable Growth Rate	58.0%	32.4%	21.0%	23.9%	29.0%	35.6%	32.8%	39.2%	45.6%	24.5%	20.7%	18.9%	19.8%	41.5%	29.4%	35.4%	37.4%	39.0%	25.5%	26.3%	26.32%
Internal Growth Rate	96.0%	37.6%	22.5%	26.5%	33.9%	45.2%	37.2%	48.0%	60.4%	25.4%	20.3%	18.2%	19.2%	51.0%	33.0%	42.6%	46.2%	49.1%	28.0%	29.2%	29.21%

Cash Flow Quality

Metric	Q2'21	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Current
OCF/Net Income	0.59	1.31	1.53	1.44	1.39	1.42	1.40	1.20	1.07	2.06	2.01	2.51	2.89	1.57	1.46	1.36	1.32	1.08	0.97	0.94	0.941
FCF/OCF	0.98	0.98	0.98	1.00	1.00	1.00	1.00	-0.36	-0.31	-0.27	-0.15	0.98	0.99	0.99	1.00	1.00	1.00	1.00	1.00	1.00	1.000
FCF/Net Income	snapshot only																				0.940
OCF/EBITDA	snapshot only																				0.664
CapEx/Revenue	0.7%	0.7%	0.7%	0.1%	0.1%	0.0%	0.0%	63.3%	53.6%	46.6%	41.4%	0.6%	0.6%	0.6%	0.1%	0.1%	0.1%	0.0%	0.0%	0.0%	0.01%
CapEx/Depreciation	snapshot only																				0.002
Accruals Ratio	0.20	-0.08	-0.10	-0.09	-0.10	-0.13	-0.11	-0.07	-0.03	-0.22	-0.17	-0.23	-0.30	-0.19	-0.11	-0.11	-0.10	-0.03	0.01	0.01	0.013
Sloan Accruals	snapshot only																				0.210
Cash Flow Adequacy	snapshot only																				2449.576
Earnings Quality Score	snapshot only																				0.750

Dividends & Buybacks

Metric	Q2'21	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Current
Dividend Yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.00%
Dividend/Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Payout Ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.00%
FCF Payout Ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	—	—	—	—	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.00%
Total Payout Ratio	5.3%	21.7%	30.6%	32.5%	27.6%	14.9%	8.3%	4.4%	0.0%	0.0%	0.0%	0.5%	0.4%	0.2%	0.2%	0.0%	0.0%	0.0%	11.8%	18.0%	18.02%
Div. Increase Streak	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Chowder Number	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Buyback Yield	0.6%	1.6%	1.6%	1.6%	2.0%	0.7%	0.3%	0.2%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.9%	1.3%	1.27%
Net Buyback Yield	0.5%	1.5%	1.6%	1.6%	2.0%	0.7%	0.2%	-0.0%	-0.3%	-0.4%	-0.1%	-7.2%	-7.3%	-5.6%	-5.3%	0.0%	-0.1%	-0.1%	0.7%	1.0%	1.03%
Total Shareholder Return	0.5%	1.5%	1.6%	1.6%	2.0%	0.7%	0.2%	-0.0%	-0.3%	-0.4%	-0.1%	-7.2%	-7.3%	-5.6%	-5.3%	0.0%	-0.1%	-0.1%	0.7%	1.0%	1.03%

DuPont Factors

Metric	Q2'21	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Current
Tax Burden (NI/EBT)	1.61	0.86	0.75	0.75	0.75	0.79	0.79	0.80	0.80	0.77	0.76	0.75	0.73	0.76	0.76	0.76	0.77	0.76	0.76	0.75	0.747
Interest Burden (EBT/EBIT)	1.01	1.01	1.01	1.00	1.00	1.01	1.01	1.02	1.03	1.03	1.09	1.10	1.09	1.09	1.11	1.12	1.10	1.07	1.07	1.08	1.076
EBIT Margin	0.36	0.36	0.37	0.39	0.43	0.44	0.49	0.48	0.46	0.22	0.22	0.19	0.20	0.38	0.40	0.43	0.44	0.46	0.45	0.46	0.461
Asset Turnover	0.83	0.88	0.65	0.71	0.79	0.89	0.70	0.84	0.99	1.14	0.94	0.97	1.03	1.09	0.74	0.81	0.85	0.88	0.60	0.61	0.610
Equity Multiplier	1.18	1.18	1.14	1.14	1.14	1.14	1.21	1.21	1.21	1.21	1.23	1.23	1.23	1.23	1.18	1.18	1.18	1.18	1.16	1.16	1.164

Per Share

Metric	Q2'21	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Current
EPS (Diluted TTM)	$0.69	$0.39	$0.36	$0.41	$0.50	$0.60	$0.73	$0.87	$1.02	$0.58	$0.63	$0.53	$0.55	$1.14	$1.30	$1.55	$1.64	$1.71	$1.68	$1.74	$1.74
Book Value/Share	$1.57	$1.57	$1.90	$1.90	$1.89	$1.85	$2.65	$2.64	$2.64	$2.82	$3.41	$3.14	$3.11	$3.09	$5.76	$5.73	$5.70	$5.73	$7.50	$7.52	$8.28
Tangible Book/Share	$1.57	$1.57	$1.90	$1.90	$1.89	$1.85	$2.36	$2.35	$2.36	$2.51	$1.70	$1.57	$1.55	$1.55	$4.52	$4.50	$4.48	$4.49	$6.46	$6.48	$6.48
Revenue/Share	$1.18	$1.24	$1.29	$1.41	$1.56	$1.71	$1.89	$2.25	$2.67	$3.27	$3.50	$3.33	$3.49	$3.67	$3.89	$4.21	$4.38	$4.55	$4.63	$4.70	$4.88
FCF/Share	$0.40	$0.49	$0.54	$0.60	$0.69	$0.85	$1.02	$-0.38	$-0.34	$-0.32	$-0.19	$1.30	$1.56	$1.77	$1.89	$2.11	$2.15	$1.85	$1.64	$1.64	$1.70
OCF/Share	$0.41	$0.50	$0.55	$0.60	$0.69	$0.85	$1.02	$1.05	$1.09	$1.20	$1.26	$1.32	$1.58	$1.79	$1.90	$2.11	$2.16	$1.85	$1.64	$1.64	$1.70
Cash/Share	$1.30	$1.30	$1.76	$1.75	$1.75	$1.71	$2.63	$2.62	$2.63	$2.80	$1.21	$1.12	$1.10	$1.10	$4.10	$4.08	$4.06	$4.07	$5.57	$5.59	$6.18
EBITDA/Share	$0.43	$0.45	$0.48	$0.55	$0.67	$0.75	$0.93	$1.14	$1.38	$0.96	$1.05	$0.92	$0.98	$1.61	$1.77	$2.05	$2.15	$2.39	$2.38	$2.47	$2.47
Debt/Share	$0.00	$0.00	$0.04	$0.04	$0.04	$0.04	$0.03	$0.03	$0.03	$0.04	$0.03	$0.03	$0.03	$0.03	$0.03	$0.03	$0.02	$0.03	$0.02	$0.02	$0.02
Net Debt/Share	$-1.30	$-1.30	$-1.72	$-1.72	$-1.71	$-1.67	$-2.59	$-2.58	$-2.59	$-2.76	$-1.18	$-1.09	$-1.08	$-1.07	$-4.07	$-4.05	$-4.03	$-4.05	$-5.55	$-5.57	$-5.57

Academic Models

Metric	Q2'21	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Current
Altman Z-Score	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	15.129
Altman Z-Prime	snapshot only																				29.124
Piotroski F-Score	6	5	6	7	6	7	7	7	7	7	6	5	5	6	6	7	6	6	6	5	5
Beneish M-Score	873.51	872.45	-2.81	-2.79	-2.75	-2.82	-2.04	-1.76	-1.71	-2.50	0.21	0.87	0.42	0.86	-2.71	-2.62	-2.64	-2.41	-1.68	-1.60	-1.603
Ohlson O-Score	snapshot only																				-12.919
ROIC (Greenblatt)	snapshot only																				36.73%
Net-Net WC	snapshot only																				$5.84
EVA	snapshot only																				$175022539.38

Credit

Metric	Q2'21	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Current
Credit Rating	snapshot only																				AA+
Credit Score	94.58	94.59	94.58	94.60	94.95	94.95	95.23	91.18	91.33	93.49	92.83	96.75	96.92	94.35	94.62	94.51	94.43	94.08	94.41	94.24	94.245
Credit Grade	snapshot only																				2
Credit Trend	snapshot only																				-0.266
Implied Spread (bps)	snapshot only																				65.000
Industry Credit Rank	snapshot only																				93
Sector Credit Rank	snapshot only																				88

CPRX NASDAQ

Edge Score

Analyst Insights

Financial Rating

InsiderStreet Scorecard

Risk & Quality Signals

Valuation

DuPont Decomposition (5-Factor)

Graham-Dodd Adjusted Valuation

Profitability Trends

Leverage & Solvency Trends

Efficiency & Working Capital Trends

Growth Trends (YoY %)

Earnings Stability

Monte Carlo Price Simulation

Executive Compensation

C-Suite Compensation

CEO Pay Ratio

C-Suite Pay Equality (Gini)

CEO Compensation Mix

Workforce & Productivity

Scaling Efficiency

Sign in to InsiderStreet